Regado Biosciences announces plans to price public offering of stock

Jefferies, Deutsche Bank and Cowen assist; deal funds clinical trials

By Devika Patel

Knoxville, Tenn., April 3 - Regado Biosciences, Inc. will price a public sale of its common stock with a 30-day greenshoe, according to a Form S-1 filed Thursday with the Securities and Exchange Commission.

Jefferies LLC, Deutsche Bank Securities Inc. and Cowen and Co. will be joint bookrunning managers.

Proceeds will be used for clinical trials, to support operations and for working capital.

The biopharmaceutical company is based in Basking Ridge, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.